Group 1 - Morgan Fund's two QDII products adjusted their large subscription thresholds rapidly, from 100,000 yuan to 10,000 yuan, and then to just 100 yuan within three days, indicating a high demand for QDII funds and cross-border asset allocation [1] - The initial increase in subscription limits for the Morgan S&P 500 Index (QDII) and Morgan Nasdaq 100 Index (QDII) attracted significant attention, leading to a surge in interest from investors who feared the quotas would be quickly exhausted [1] - Many QDII products are currently under significant purchase restrictions, with other funds like Southern Nasdaq 100 Index (QDII) and Huatai-PineBridge Nasdaq Biotechnology ETF (QDII) also lowering their subscription limits to 50 yuan and 200 yuan respectively [2] Group 2 - Some QDII products that can be traded in the secondary market are experiencing a "high premium" status due to supply-demand imbalances caused by purchase restrictions, as seen with the Invesco Great Wall Nasdaq Technology ETF (QDII) which was temporarily suspended for trading due to premium risks [3] - The high premiums are attributed to limited offshore quotas leading investors to turn to secondary market trading, resulting in crowded transactions and inflated prices driven by optimistic expectations for overseas assets [3] - Industry experts caution that investors should not blindly chase QDII products with opened quotas, as this does not guarantee good performance or an ideal investment opportunity, advising a rational approach to investment decisions [3]

Market Performance - On May 26, the market experienced fluctuations with the ChiNext Index leading the decline. Sectors such as controllable nuclear fusion, smart logistics, PEEK materials, and IP economy saw significant gains, while innovative drugs, complete automobiles, traditional Chinese medicine, and vitamins faced notable declines. Over 3,700 stocks rose across the market [1] - The total trading volume in the Shanghai and Shenzhen markets was 1.01 trillion yuan, a decrease of 145.6 billion yuan compared to the previous trading day [1] Fund Performance - The top-performing funds for the day included: - Huaxia High-end Manufacturing A with a daily net value growth rate of 2.96% and a year-to-date return of -2.8% [2] - Xinhua Technology Innovation Theme with a daily growth of 2.78% and a year-to-date return of -5.84% [2] - China Merchants Sports Culture Leisure A with a daily growth of 2.69% and a year-to-date return of 5.06% [2] - The fund with the highest year-to-date return was the China Merchants North Exchange Innovation Small and Medium Enterprises Selected Fund, which rose approximately 1.4% on the day, bringing its year-to-date return to 68.51% [4] QDII Fund Insights - The QDII product, Huatai-PineBridge Hong Kong Advantage Selection, briefly topped the year-to-date return list but is expected to see a decline due to the weak performance of its major holdings in Hong Kong pharmaceutical stocks [3] - As of the latest data, the Huatai-PineBridge Hong Kong Advantage Selection A fund had a year-to-date return of 68.45%, leading the QDII products by a significant margin [6] Sector-Specific Insights - The pharmaceutical sector showed mixed results, with notable declines in stocks such as Hansoh Pharmaceutical (-0.19% for the day, 48.15% year-to-date) and Innovent Biologics (-2.45% for the day, 68.95% year-to-date) [4] - The market's top-performing fund in the North Exchange theme was the China Merchants North Exchange Selected Fund, which achieved a year-to-date return of 68.08% [5]